GlaxoSmithKline
Executive Summary
SmithKline Beecham VP-Federal Government Affairs Patrick McClain will remain with the merged company, whose D.C. office will be headed by Glaxo Wellcome VP-Government Affairs & Public Policy Janie Kinney. SB VP and Government Relations Director Burt Rosen recently joined Novartis' D.C. office as VP-pharmaceutical government relations (1"The Pink Sheet" Sept. 4, p. 28)
You may also be interested in...
Novartis
SmithKline Beecham VP and Government Relations Director Burt Rosen will join Novartis' D.C. office as VP-pharmaceutical government relations Oct. 1. Glaxo Wellcome VP-Federal Government Relations & Public Policy Janie Kinney is slated to head the combined GlaxoSmithKline D.C. office following completion of the merger
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials